RU2008129623A - Ингибиторы ccr9 активности - Google Patents
Ингибиторы ccr9 активности Download PDFInfo
- Publication number
- RU2008129623A RU2008129623A RU2008129623/04A RU2008129623A RU2008129623A RU 2008129623 A RU2008129623 A RU 2008129623A RU 2008129623/04 A RU2008129623/04 A RU 2008129623/04A RU 2008129623 A RU2008129623 A RU 2008129623A RU 2008129623 A RU2008129623 A RU 2008129623A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- indole
- dihydro
- tert
- alkyl
- Prior art date
Links
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 title claims abstract 5
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 title claims abstract 5
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 title claims abstract 5
- 230000000694 effects Effects 0.000 title claims abstract 5
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 19
- 229910052736 halogen Chemical group 0.000 claims abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 6
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract 5
- 229940088679 drug related substance Drugs 0.000 claims abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 208000035475 disorder Diseases 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 4
- 230000001404 mediated effect Effects 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 3
- YHVRASJUAPKAJF-UHFFFAOYSA-N 1-(4-tert-butylphenyl)sulfonyl-2,3-dihydroindole-2-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1S(=O)(=O)N1C2=CC=CC=C2CC1C(O)=O YHVRASJUAPKAJF-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract 2
- UFOAJMITESDPND-UHFFFAOYSA-N 5-bromo-1-(4-tert-butylphenyl)sulfonyl-2,3-dihydroindole-2-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1S(=O)(=O)N1C2=CC=C(Br)C=C2CC1C(O)=O UFOAJMITESDPND-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims abstract 2
- 125000005843 halogen group Chemical group 0.000 claims abstract 2
- 150000002367 halogens Chemical group 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- FTOLUNCLSMLFDK-UHFFFAOYSA-N methyl 5-bromo-1-(4-tert-butylphenyl)sulfonyl-2,3-dihydroindole-2-carboxylate Chemical compound COC(=O)C1CC2=CC(Br)=CC=C2N1S(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 FTOLUNCLSMLFDK-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 125000001424 substituent group Chemical group 0.000 claims abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- RVCQVOIXDZORGB-UHFFFAOYSA-N methyl 1-(4-tert-butylphenyl)sulfonyl-2,3-dihydroindole-2-carboxylate Chemical compound COC(=O)C1CC2=CC=CC=C2N1S(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 RVCQVOIXDZORGB-UHFFFAOYSA-N 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- -1 halo (C1-C4) alkyl Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
Abstract
1. Соединение формулы ! ! в которой ! R1 означает водород, (С1-С6)алкил, гало(С1-С4)алкил, (С1-С4)алкокси, галоалкилокси, или галоид, ! R2 означает фенил, замещенный одним или более заместителями: ! - C1-С6алкилом, ! - галоС1-С4алкилом, ! - С1-С4алкокси, ! - галоС1-С4алкокси, или ! - галоидом; и ! R3 означает карбокси, С1-С4алкоксикарбонил или циано. ! 2. Соединение по п.1, в котором ! R1 означает C1-С6алкил, ! R2 означает незамещенный фенил или фенил, замещенный галоидом, и ! R3 означает С1-С4алкокеикарбонил. ! 3. Соединение по п.1, выбранное из группы, состоящей из ! метилового эфира 1-(4-трет-бутилбензенсульфонил)-2,3-дигидро-1Н-индол-2-карбоновой кислоты, ! 1-(4-трет-бутилбензенсульфонил)-2,3-дигидро-1Н-индол-2-карбоновой кислоты, ! метилового эфира 5-бром-1-(4-трет-бутилбензенсульфонил)-2,3-дигидро-1Н-индол-2-карбоновой кислоты, и ! 5-бром-1-(4-трет-бутилбензенсульфонил)-2,3-дигидро-1Н-индол-2-карбоновой кислоты. ! 4. Соединение по п.1 в форме соли. ! 5. Соединение по п.3 в виде соли. ! 6. Соединение по любому из пп.1-5 для применения в качестве лекарства. ! 7. Фармацевтическая композиция, включающая соединение по любому из пп.1-5 в сочетании с по крайней мере одним фармацевтически приемлемым наполнителем. ! 8. Применение соединения по любому из пп.1-5 для получения лекарства для лечения нарушений, опосредованных CCR9 активностью. ! 9. Фармацевтическая комбинация, включающая соединение по любому из пп.1-5, включающая, кроме того, вторую лекарственную субстанцию. ! 10. Фармацевтическая комбинация, включающая фармацевтическую композицию по п.7 и дополнительно включающая второе лекарственное вещество. ! 11. Способ лечения нарушений, опосредованных CCR9 активностью, включающий введение субъекту, нуждающе�
Claims (11)
1. Соединение формулы
в которой
R1 означает водород, (С1-С6)алкил, гало(С1-С4)алкил, (С1-С4)алкокси, галоалкилокси, или галоид,
R2 означает фенил, замещенный одним или более заместителями:
- C1-С6алкилом,
- галоС1-С4алкилом,
- С1-С4алкокси,
- галоС1-С4алкокси, или
- галоидом; и
R3 означает карбокси, С1-С4алкоксикарбонил или циано.
2. Соединение по п.1, в котором
R1 означает C1-С6алкил,
R2 означает незамещенный фенил или фенил, замещенный галоидом, и
R3 означает С1-С4алкокеикарбонил.
3. Соединение по п.1, выбранное из группы, состоящей из
метилового эфира 1-(4-трет-бутилбензенсульфонил)-2,3-дигидро-1Н-индол-2-карбоновой кислоты,
1-(4-трет-бутилбензенсульфонил)-2,3-дигидро-1Н-индол-2-карбоновой кислоты,
метилового эфира 5-бром-1-(4-трет-бутилбензенсульфонил)-2,3-дигидро-1Н-индол-2-карбоновой кислоты, и
5-бром-1-(4-трет-бутилбензенсульфонил)-2,3-дигидро-1Н-индол-2-карбоновой кислоты.
4. Соединение по п.1 в форме соли.
5. Соединение по п.3 в виде соли.
6. Соединение по любому из пп.1-5 для применения в качестве лекарства.
7. Фармацевтическая композиция, включающая соединение по любому из пп.1-5 в сочетании с по крайней мере одним фармацевтически приемлемым наполнителем.
8. Применение соединения по любому из пп.1-5 для получения лекарства для лечения нарушений, опосредованных CCR9 активностью.
9. Фармацевтическая комбинация, включающая соединение по любому из пп.1-5, включающая, кроме того, вторую лекарственную субстанцию.
10. Фармацевтическая комбинация, включающая фармацевтическую композицию по п.7 и дополнительно включающая второе лекарственное вещество.
11. Способ лечения нарушений, опосредованных CCR9 активностью, включающий введение субъекту, нуждающемуся в таком лечении, терапевтически эффективного количества соединения по любому из пп.1-5 необязательно в комбинации со второй лекарственной субстанцией.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0526257.1A GB0526257D0 (en) | 2005-12-22 | 2005-12-22 | Organic compounds |
| GB0526257.1 | 2005-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008129623A true RU2008129623A (ru) | 2010-01-27 |
Family
ID=35841080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008129623/04A RU2008129623A (ru) | 2005-12-22 | 2006-12-22 | Ингибиторы ccr9 активности |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7781481B2 (ru) |
| EP (1) | EP1968939A2 (ru) |
| JP (1) | JP2009519990A (ru) |
| KR (1) | KR20080070077A (ru) |
| CN (1) | CN101326164A (ru) |
| AU (1) | AU2006328902A1 (ru) |
| BR (1) | BRPI0620208A2 (ru) |
| CA (1) | CA2631069A1 (ru) |
| GB (1) | GB0526257D0 (ru) |
| RU (1) | RU2008129623A (ru) |
| WO (1) | WO2007071442A2 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009039344A1 (en) * | 2007-09-21 | 2009-03-26 | Harry Fisch | Treatment of migraine headaches using antiestrogens |
| CN104080451B (zh) | 2011-09-15 | 2016-08-24 | 台北医学大学 | 吲哚异羟肟酸和吲哚啉异羟肟酸于治疗心脏衰竭或神经损伤的用途 |
| WO2013190497A2 (en) * | 2012-06-21 | 2013-12-27 | Radikal Therapeutics Inc. | Compositions and methods for treatment of inflammatory diseases of the lung |
| TW201438717A (zh) | 2012-12-04 | 2014-10-16 | Takeda Pharmaceutical | 預防或治療蕭格倫徵候群之方法 |
| WO2017140793A1 (en) * | 2016-02-16 | 2017-08-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Modulators of ccr9 for treating tumor resistance to immune responses |
| GB201917101D0 (en) * | 2019-11-25 | 2020-01-08 | Uea Enterprises Ltd | Method for digesting nucleic acid in a sample |
| EP4472741A1 (en) * | 2022-02-03 | 2024-12-11 | SunRock Biopharma S.L. | Combination therapy comprising anti-ccr9 antibody and vincristine for cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795890A (en) | 1995-09-27 | 1998-08-18 | Ono Pharmaceutical Co., Ltd. | Sulfonamide derivatives |
| ATE213232T1 (de) | 1995-11-13 | 2002-02-15 | Hoechst Ag | Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren |
| US6559127B1 (en) * | 1997-07-31 | 2003-05-06 | Athena Neurosciences, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| CO5011105A1 (es) | 1997-12-22 | 2001-02-28 | Novartis Ag | Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion |
| AU1918299A (en) | 1998-02-23 | 1999-09-06 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
| US6251932B1 (en) | 1998-09-25 | 2001-06-26 | Asta Medica Ag | Immunophilin ligands |
| WO2000035877A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | Heterocyclic piperidines as modulators of chemokine receptor activity |
| GB9902455D0 (en) * | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB2392507B (en) | 2001-07-06 | 2005-03-09 | Honda Motor Co Ltd | Vehicle crash test apparatus |
| US6649606B1 (en) | 2001-11-09 | 2003-11-18 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| TW200303742A (en) * | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| WO2003058304A2 (en) | 2002-01-09 | 2003-07-17 | Micro Managed Photons A/S | Light localization structures for guiding electromagnetic waves |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| CA2515780C (en) | 2003-02-20 | 2012-12-11 | Encysive Pharmaceuticals Inc. | Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| EP1651595A2 (en) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| US20050182060A1 (en) | 2004-02-13 | 2005-08-18 | Kelly Michael G. | 2-Substituted and 4-substituted aryl nitrone compounds |
| EP1724263B1 (en) | 2004-03-10 | 2014-03-05 | Kureha Corporation | Basic amine compound and use thereof |
| ES2390057T3 (es) | 2004-04-20 | 2012-11-06 | Amgen Inc. | Arilsulfonilamidas y usos como hidroxiesteroide deshidrogenasa |
| FR2869904B1 (fr) | 2004-05-07 | 2006-07-28 | Fournier S A Sa Lab | Modulateurs des recepteurs lxr |
| WO2005113513A2 (en) * | 2004-05-12 | 2005-12-01 | Chemocentryx | Aryl sulfonamides |
| CA2567343A1 (en) * | 2004-05-20 | 2005-12-01 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| GB0412467D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| DE102004033834A1 (de) | 2004-07-13 | 2006-02-02 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel |
| FR2886293B1 (fr) * | 2005-05-30 | 2007-08-24 | Fournier S A Sa Lab | Nouveaux composes de l'indoline |
-
2005
- 2005-12-22 GB GBGB0526257.1A patent/GB0526257D0/en not_active Ceased
-
2006
- 2006-12-22 RU RU2008129623/04A patent/RU2008129623A/ru not_active Application Discontinuation
- 2006-12-22 CN CNA2006800458691A patent/CN101326164A/zh active Pending
- 2006-12-22 EP EP06829849A patent/EP1968939A2/en not_active Withdrawn
- 2006-12-22 US US12/158,369 patent/US7781481B2/en not_active Expired - Fee Related
- 2006-12-22 AU AU2006328902A patent/AU2006328902A1/en not_active Abandoned
- 2006-12-22 WO PCT/EP2006/012475 patent/WO2007071442A2/en active Application Filing
- 2006-12-22 KR KR1020087015003A patent/KR20080070077A/ko not_active Ceased
- 2006-12-22 CA CA002631069A patent/CA2631069A1/en not_active Abandoned
- 2006-12-22 BR BRPI0620208-0A patent/BRPI0620208A2/pt not_active Application Discontinuation
- 2006-12-22 JP JP2008546282A patent/JP2009519990A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006328902A1 (en) | 2007-06-28 |
| JP2009519990A (ja) | 2009-05-21 |
| CN101326164A (zh) | 2008-12-17 |
| BRPI0620208A2 (pt) | 2011-11-01 |
| WO2007071442A2 (en) | 2007-06-28 |
| WO2007071442A3 (en) | 2007-08-16 |
| KR20080070077A (ko) | 2008-07-29 |
| US7781481B2 (en) | 2010-08-24 |
| GB0526257D0 (en) | 2006-02-01 |
| EP1968939A2 (en) | 2008-09-17 |
| CA2631069A1 (en) | 2007-06-28 |
| US20080269312A1 (en) | 2008-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
| RU2008129723A (ru) | Ингибиторы ccr9 активности | |
| RU2009135621A (ru) | Хинолиновые производные для лечения воспалительных заболеваний | |
| EA201171333A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| MX2007010532A (es) | Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii. | |
| RU2013119129A (ru) | Органические соединения | |
| EA200400953A1 (ru) | Замещённые пиридиноны в качестве модуляторов map-киназы p38 | |
| RU2008129623A (ru) | Ингибиторы ccr9 активности | |
| EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
| EA201101671A1 (ru) | Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина | |
| NO20091560L (no) | Biaryleterureaforbindelser | |
| RU2014103587A (ru) | Производные циклических аминов в качестве антагонистов рецептора ер4 | |
| EA200700099A1 (ru) | Производные пиридина | |
| NO20090327L (no) | Nye forbindelser 384 | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| RU2008129635A (ru) | Ингибиторы ссr9 активности | |
| NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| JP2008530242A5 (ru) | ||
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| RU2007106180A (ru) | Производные индола, индазола или индолина | |
| RU2394031C2 (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| RU2006130000A (ru) | Органические соединения | |
| CY1109376T1 (el) | Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης | |
| ATE440833T1 (de) | Antithrombotische diamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20101109 |